Key takeaways
Darifenacin (formerly branded as Enablex) and fesoterodine (Toviaz) are both urinary antispasmodics used to treat overactive bladder (OAB). Darifenacin is only approved for OAB in adults, while fesoterodine is also approved for neurogenic detrusor overactivity (NDO) in children aged 6 and older. Both medications are taken once a day and are available in generic forms. Darifenacin works by blocking certain receptors in the bladder to relax the muscles, whereas fesoterodine blocks acetylcholine to achieve a similar effect. Common side effects for both include dry mouth and constipation, but fesoterodine has a higher risk of drug interactions. Additionally, darifenacin is generally not recommended for those 65 or older due to increased risk of dizziness and drowsiness, while fesoterodine has specific contraindications for those allergic to tolterodine.
